Clarivate (CLVT) Q2 2026 earnings call transcript details financial results, performance metrics and forward outlook. Earnings call transcript delivers core financial results and guidance that directly shape investor views and company trajectory.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | 2 | 1 | — | — | — | — | — | — | — | — | 1 | — |
| Sell | — | — | 1 | — | — | — | — | — | — | — | 1 | — |
| total | individual payouts | |
|---|---|---|
| 2025 | ‡‡‡ |
|
| 2024 | ‡‡‡ |
|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡‡ |
|
| 2019 | ‡‡‡‡ |
|
| 2017 | ‡‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 370.70 | 295.20 | 329.20 | 217.70 |
| Receivables | 908.30 | 798.30 | 821.70 | 827.90 |
| Inventory | — | — | — | — |
| Other | 183.20 | 151.10 | 159.10 | 168.60 |
| 1,462.20 | 1,244.60 | 1,310.00 | 1,214.20 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 144.10 | 124.50 | 150.60 | 152.90 |
| ST’ Debt | — | 1.30 | 101.50 | 1.60 |
| Other | 6.70 | — | — | — |
| 1,600.00 | 1,433.50 | 1,568.80 | 1,435.70 |
| 10y | 5y | 3y | |
| Sales | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 585.50 | 587.30 | — | — |
—
|
| ’25 | 593.70 | 621.40 | 623.10 | 617.00 |
2,455.20
|
| ’24 | 621.20 | 650.30 | 622.20 | 663.00 |
2,556.70
|
| ’23 | 629.10 | 668.80 | 647.20 | 683.70 |
2,628.80
|
| ’22 | 662.20 | 686.60 | 635.70 | 675.30 |
2,659.80
|
| ’21 | 428.40 | 445.70 | 442.10 | 560.70 |
1,876.90
|
| ’20 | 240.59 | 273.50 | 284.36 | 455.65 |
1,254.10
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 134.70 | 98.70 | — | — |
—
|
| ’25 | 171.20 | 116.30 | 181.10 | 159.90 |
628.50
|
| ’24 | 176.20 | 126.20 | 202.90 | 141.30 |
646.60
|
| ’23 | 227.50 | 162.40 | 163.40 | 190.90 |
744.20
|
| ’22 | 67.40 | 97.20 | 207.80 | 136.90 |
509.30
|
| ’21 | 174.00 | 87.70 | 43.80 | 18.30 |
323.80
|
| ’20 | 46.11 | 61.46 | 20.46 | 135.48 |
263.50
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 78.90 | 44.00 | — | — |
—
|
| ’25 | 110.30 | 50.30 | 115.50 | 89.20 |
365.30
|
| ’24 | 111.80 | 60.30 | 126.30 | 59.10 |
357.50
|
| ’23 | 168.20 | 104.80 | 101.70 | 127.00 |
501.70
|
| ’22 | 26.00 | 49.50 | 140.40 | 90.50 |
306.40
|
| ’21 | 141.00 | 58.70 | 19.60 | (14.00) |
205.30
|
| ’20 | 26.71 | 22.22 | (5.49) | 106.38 |
149.82
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.06) | (0.42) | — | — |
—
|
| ’25 | (0.15) | (0.11) | (0.04) | 0.00 |
(0.30)
|
| ’24 | (0.14) | (0.46) | (0.09) | (0.27) |
(0.96)
|
| ’23 | 0.04 | (0.21) | (0.01) | (1.30) |
(1.47)
|
| ’22 | (0.06) | 0.06 | (6.64) | 0.44 |
(6.24)
|
| ’21 | (0.04) | (0.13) | 0.00 | (0.20) |
(0.61)
|
| ’20 | (0.22) | 0.00 | (0.10) | 0.01 |
(0.25)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 7.85 | 6.07 | 4.25 | 3.04 | — | — | — |
Low Price
|
| — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 24.85 | 11.99 | 9.61 | 5.74 | — | — | — |
High Price
|
| — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 11,800 | 12,000 | 12,000 | 12,000 | — | — | — |
Employees
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.23 | 0.22 | 0.21 | 0.20 | — | — | — |
Revenue/Emp
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2,659.80 | 2,628.80 | 2,556.70 | 2,455.20 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 64.13% | 65.52% | 66.00% | 66.05% | — | — | — |
Gross Margin
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (3,989.10) | (1,012.50) | (553.80) | (193.90) | — | — | — |
EBT
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (149.98%) | (38.52%) | (21.66%) | (7.90%) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (3,960.20) | (911.20) | (636.70) | (201.10) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 710.50 | 708.30 | 727.00 | 757.20 | — | — | — |
Depreciation
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.93 | 3.91 | 3.69 | 3.65 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (5.97) | (1.47) | (0.96) | (0.30) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.75 | 1.11 | 0.93 | 0.93 | — | — | — |
Cash Flow/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.30) | (0.36) | (0.42) | (0.39) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.45 | 0.75 | 0.52 | 0.54 | — | — | — |
Free CF/Sh
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | 10.08 | 8.92 | 7.41 | 7.19 | — | — | — |
Book Value/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 676.10 | 671.60 | 693.60 | 673.30 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
PE Ratio
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.17 | 2.32 | 1.38 | 0.92 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.07 | 1.33 | 0.69 | 0.46 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.92 | 3.98 | 3.03 | 2.58 | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 34.70 | 21.08 | 22.04 | 17.65 | — | — | — |
EV/FCF
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 509.30 | 744.20 | 646.60 | 628.50 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (202.90) | (242.50) | (289.10) | (263.20) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Capex
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 306.40 | 501.70 | 357.50 | 365.30 | — | — | — |
FCF
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (164.60) | (137.80) | (188.90) | (258.80) | — | — | — |
Working Cap'
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5,006.00 | 4,721.10 | 4,520.00 | 4,423.00 | — | — | — |
Total Debt
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4,649.20 | 4,350.40 | 4,224.80 | 4,093.80 | — | — | — |
Net Debt
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6,812.50 | 5,992.30 | 5,139.00 | 4,842.90 | — | — | — |
Sh' Equity
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (23.65%) | (7.40%) | (5.52%) | (1.78%) | — | — | — |
ROA
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (21.41%) | (4.44%) | (1.84%) | 0.50% | — | — | — |
ROIC
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (50.59%) | (19.69%) | (13.72%) | (4.03%) | — | — | — |
ROE
|
Clarivate PLC (CLVT) is poised at an electrifying inflection point, trading near multi-year lows after a decade of bold acquisitive growth that ballooned revenue 175% from $968 million in 2018 to $2.66 billion in 2022. Despite recent dips and profitability headwinds from integration costs and impairments—culminating in massive 2022 losses—emerging stabilizers like rising gross margins to 66%, resilient free cash flow per share at $0.52 (up 44% from 2021), and strong insider buying ($9.85 million in purchases vs. $1.61 million sells, a 5.1x imbalance) signal a powerful rebound brewing.
Analyst forecasts ignite optimism, projecting 31% revenue growth to $3.35 billion in 2025, flipping EBT positive at $229 million, and delivering mean price targets implying a staggering 121% upside (up to 287% on the high end). At just 1.4x PS and 0.69x PB—deeply discounted versus peers like Moody’s—Clarivate’s moat in IP, science, and academic analytics positions it perfectly for AI/biotech patent booms and ProQuest synergies.
Risks like high debt ($4.52 billion) and capex spikes demand caution, but with FCF projected over $1 billion and ROE potentially hitting 16%, this disrupted innovator offers explosive potential for patient growth seekers eyeing the next cycle’s winners.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.